Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Active ingredients: ranibizumab
What it is used for
Lucentis (ranibizumab) is indicated in adults for:, the treatment of neovascular (wet) age-related macular degeneration (AMD), the treatment of visual impairment due to diabetic macular oedema (DME), treatment of proliferative diabetic retinopathy (PDR), the treatment of visual impairment due to choroidal neovascularisation, the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).,Lucentis is indicated in preterm infants for:, the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
How to take it
The way to take this medicine is: Intravitreal-Within The Vitreous Cavity Of The Eye.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on June 1, 2022. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient ranibizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.